Thalia Therapeutics Begins Preclinical Work on Proposed Cardiovascular Disease Therapy

05:31 AM EDT, 09/25/2026 (MT Newswires) -- Thalia Therapeutics (THAT.L) started preclinical work for THAT-002, its investigative dual-acting siRNA therapeutic targeting cardiovascular disease risk factors PCSK9 and lipoprotein(a). The preclinical work is being carried out with WuXi AppTec (Hong Kong) and follows the completion of the initial chemistry synthesis of the siRNA gene-silencing medicines under the THAT-002 cardiovascular program, the biotechnology company said Friday.